Back

Reduction of LDL-C-related residual cardiovascular risk with ezetimibe: are mechanistic considerations warranted in practice?

European Heart Journal

19 May 2017
Organised by: Logo
Read full article
ESC Journals PREVENTIVE CARDIOLOGY Risk Factors and Prevention
You may be interested in
thumbnail
Congress Presentation
Impact of bempedoic acid alone and combined with ezetimibe on ldl-cholesterol reduction: graphical evidence and retrospective analysis of a real-world clinical cohort
24 April 2026
thumbnail
Webinar
Lipid management pathways and ESC Guidelines
10 January 2023
thumbnail
Congress Presentation
Impact of calculated LDL-c on residual cardiovascular risk assessment
23 April 2026
thumbnail
Congress Presentation
NATURE-LEGACY: Long term legacy benefit of Lowering LDL and SBP
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources